Molecule Holdings launches Covid-19 kits for immediate distribution

Molecule Holdings has launched its coronavirus (Covid-19) diagnosis test kits for immediate distribution to medical professionals, following its emergency use authorisation (EUA) by the US Food and Drug Administration (FDA).

The FDA-approved Rapid Covid-19 Test kits provide results in five minutes. Credit: Molecule Holdings.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.

by GlobalData

Enter your details here to receive your free Report.

By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Follow the latest updates of the outbreak on our timeline.

Reports

View All

The Covid Care Rapid test detects IgG and IgM antibodies to SARS-CoV-2 in human blood and delivers results in five minutes. It is said to have a 91% clinical sensitivity rating and a 99% clinical specificity rating.

Furthermore, the test offers affordable, point-of-care testing compared to PCR technology-based coronavirus tests, which take multiple days to show results.

The Covid Care Rapid test was developed by Pinnacle BioLabs. It is manufactured in ISO -13485 certified facility.

Prior to the launch, the test has undergone significant preliminary clinical testing and can provide diagnostic specificity higher than 90%.

The test kit contains a lancet to prick the finger and testing cassette to place blood drops. It also comes with a testing solution, which has to be mixed with the obtained blood to get the result.

The testing process is similar to the tests used by diabetics to test their blood sugar.

Molecule Holdings will soon provide the test kits to medical professionals, first responders and law enforcement.

Meanwhile, medical companies and laboratories across the US are striving to develop and produce more Covid-19 detection tests to meet the increasing demand.

Recently, FDA granted EUA to several companies, including Bodysphere, Luminex, and Abbott for their Covid-19 detection tests.

According to the latest reports, there are more than 216,721 confirmed coronavirus cases and 5,138 deaths in the US.